WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017180769) SMALL MOLECULES FOR IMMUNOGENIC TREATMENT OF CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/180769 International Application No.: PCT/US2017/027248
Publication Date: 19.10.2017 International Filing Date: 12.04.2017
IPC:
A61K 39/395 (2006.01) ,A61K 45/06 (2006.01) ,C07C 15/04 (2006.01)
Applicants: CAPTEN THERAPEUTICS INC.[US/US]; 5 Walnut Hill Park, Suite 13C Woburn, Massachusetts 01801, US
Inventors: CHIMMANAMADA, Dinesh; US
YING, Weiwen; US
Agent: PEARL COHEN ZEDEK LATZER BARATZ LLP; 1500 Broadway, 12th Floor New York, New York 10036, US
COHEN, Mark; US
Priority Data:
62/322,06813.04.2016US
Title (EN) SMALL MOLECULES FOR IMMUNOGENIC TREATMENT OF CANCER
(FR) PETITES MOLÉCULES POUR LE TRAITEMENT IMMUNOGÈNE DU CANCER
Abstract: front page image
(EN) The present invention relates to new compounds for immunogenic treatment of cancer. The compounds can be administered as a single agent or in combination with an anticancer drug including modulators of other immune pathways, especially immune checkpoint inhibitors that target CTLA-4, PD-1, and PD-L1 proteins. The compounds can produce neoantigens through irreversible protein binding in cancer cells and generate immune response.
(FR) La présente invention concerne de nouveaux composés pour le traitement immunogène du cancer. Les composés peuvent être administrés sous forme d'agent individuel ou en association avec un anticancéreux comprenant des modulateurs d'autres voies immunitaires, notamment des inhibiteurs des points de contrôle immunitaire qui ciblent les protéines CTLA-4, PD-1 et PD-L1. Les composés peuvent produire des néoantigènes par liaison irréversible des protéines dans des cellules cancéreuses et générer une réponse immunitaire.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)